Русский
Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data
DOI: https://dx.doi.org/10.18565/pharmateca.2023.12.98-106
A.V. Matveev, S.V. Glagolev, D.A. Sychev
Department of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Background. Thromboembolic complications are the one the factors that plays a significant role in the increase in mortality and disability of the population. The main role in their treatment and prevention belongs to anticoagulants, incl. oral anticoagulants (OACs), which include rivaroxaban, apixaban and dabigatran. OACs have gained particular importance in the context of the novel coronavirus infection (COVID-19) pandemic.
Objective. Evaluation of the consumption of OACs in hospitals in the Russian Federation for the period from 2017 to 2022 and the characteristics of their consumption during the COVID-19 pandemic.
Methods. The database of OOO Cursor Marketing LLC was used as a data source. Data on contracts concluded between 01/01/2017 and 12/31/2022 were analyzed. Data published by WHO from March 1, 2020 to December 31, 2022 were used as a source of data on morbidity and mortality from COVID-19. Consumption was calculated based on DDD (Defined Daily Dose) data presented on the WHO Collaborating Center website.
Results. Total for the period 2017–2022. 57,866 records were entered into the Cursor databases, of which 47.38% of records contained an indication that the purchased drug was rivaroxaban, 26.51% – dabigatran and 26.11% – apixaban. There was a drop in the number of contracts in 2022; from 2017 to 2021, their number grew, with the increase being more pronounced for apixaban and the least significant for dabigatran. Similar dynamics were observed for the volume of contracts, expressed in the number of packages and DDD; 97% of all contracts were concluded for a period of one year. For all analyzed time series, the presence of seasonality was found. The number of packages purchased and the DDD of rivaroxaban (P<0.05) and apixaban (P<0.001) purchased were correlated with rates of new illness and death from COVID-19.
Conclusion. The problem of studying the dynamics of OAC consumption is of significant practical interest. The number of requests for the purchase of OACs in Russian hospitals is increasing, and the COVID-19 pandemic has had a significant impact on the procurement structure.
Objective. Evaluation of the consumption of OACs in hospitals in the Russian Federation for the period from 2017 to 2022 and the characteristics of their consumption during the COVID-19 pandemic.
Methods. The database of OOO Cursor Marketing LLC was used as a data source. Data on contracts concluded between 01/01/2017 and 12/31/2022 were analyzed. Data published by WHO from March 1, 2020 to December 31, 2022 were used as a source of data on morbidity and mortality from COVID-19. Consumption was calculated based on DDD (Defined Daily Dose) data presented on the WHO Collaborating Center website.
Results. Total for the period 2017–2022. 57,866 records were entered into the Cursor databases, of which 47.38% of records contained an indication that the purchased drug was rivaroxaban, 26.51% – dabigatran and 26.11% – apixaban. There was a drop in the number of contracts in 2022; from 2017 to 2021, their number grew, with the increase being more pronounced for apixaban and the least significant for dabigatran. Similar dynamics were observed for the volume of contracts, expressed in the number of packages and DDD; 97% of all contracts were concluded for a period of one year. For all analyzed time series, the presence of seasonality was found. The number of packages purchased and the DDD of rivaroxaban (P<0.05) and apixaban (P<0.001) purchased were correlated with rates of new illness and death from COVID-19.
Conclusion. The problem of studying the dynamics of OAC consumption is of significant practical interest. The number of requests for the purchase of OACs in Russian hospitals is increasing, and the COVID-19 pandemic has had a significant impact on the procurement structure.
About the Autors
Corresponding author: Aleksandr V. Matveev, Cand. Sci. (Med.), Associate Professor at the Department of Clinical Pharmacology and Therapy n.a. acad. B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; matveevav@rmapo.ru
Similar Articles
